Microbiota–gut–brain axis: Natural antidepressants molecular mechanism

• Published in: Phytomedicine (Stuttgart) Vol. 134; p. 156012
• Main Authors: Lu, Yitong, Yu, Xiaowen, Wang, Zhongling, Kong, Linghui, Jiang, Zhenyuan, Shang, Ruirui, Zhong, Xia, Lv, Shimeng, Zhang, Guangheng, Gao, Haonan, Yang, Ni
• Format: Journal Article
• Language: English
• Published: Germany Elsevier GmbH 01-11-2024
• Subjects: Animals; Antidepressant; Antidepressive Agents - pharmacology; Biological Products - pharmacology; Brain - drug effects; Brain-Gut Axis - drug effects; Brain-Gut Axis - physiology; Depression; Depressive Disorder, Major - drug therapy; Gastrointestinal Microbiome - drug effects; Gut microbiota; Humans; Microbiota-gut-brain axis; Molecular mechanism; Natural products; Gut microbiota; SCP; Microbiota-gut-brain axis; BBB; SSRIs; CPT; AHN; CUMS; ACTH; GPR; MDD; PRS; Glu; NAc; NF-κB; AS-IV; BBR; Trp; PI3K; BAs; PROEs; VJJ; FFAR2; CYP; Th17; EC; MAOIs; Kyn; EPs; 5-HTP; IL-1β; MAPK; PSP; IL-6; GEO; NSCs; IAld; RE; ZO-1; CRF; Trp-Kyn; NE; ROS; GABA; HPA; VN; 5-HT; PCO; TLR4; ERK; IDO1; Kna; Antidepressant; TPH1; Molecular mechanism; ANS; CNS; ENS; GBE; GCDCA; LPS; INU; NAOs; RPP; PLP; SNRIs; CDPs; GC; GF; OP; GCA; BDNF; ACH; GM; ICA; Treg; Depression; MGB; Akt; MOO; Cort; MPP8; NPs; TNF-α; WGE; Natural products; LA; APE; NPCs; rmTBI; SCFAs; DA; ILA
• ISSN: 0944-7113; 1618-095X; 1618-095X
• DOI: 10.1016/j.phymed.2024.156012

•Natural products have unique advantages in the treatment of depression.•The imbalance of gut microbiota is closely related to depression.•Natural products can treat depression by regulating gut microbiota.
Major depressive disorder (MDD) is a severe mental health condition characterized by persistent depression, impaired cognition, and reduced activity. Increasing evidence suggests that gut microbiota (GM) imbalance is closely linked to the emergence and advancement of MDD, highlighting the potential significance of regulating the "Microbiota-Gut-Brain" (MGB) axis to impact the development of MDD. Natural products (NPs), characterized by broad biological activities, low toxicity, and multi-target characteristics, offer unique advantages in antidepressant treatment by regulating MGB axis.
This review was aimed to explore the intricate relationship between the GM and the brain, as well as host responses, and investigated the mechanisms underlying the MGB axis in MDD development. It also explored the pharmacological mechanisms by which NPs modulate MGB axis to exert antidepressant effects and addressed current research limitations. Additionally, it proposed new strategies for future preclinical and clinical applications in the MDD domain.
To study the effects and mechanism by which NPs exert antidepressant effects through mediating the MGB axis, data were collected from Web of Science, PubMed, ScienceDirect from initial establishment to March 2024. NPs were classified and summarized by their mechanisms of action.
NPs, such as flavonoids,alkaloids,polysaccharides,saponins, terpenoids, can treat MDD by regulating the MGB axis. Its mechanism includes balancing GM, regulating metabolites and neurotransmitters such as SCAFs, 5-HT, BDNF, inhibiting neuroinflammation, improving neural plasticity, and increasing neurogenesis.
NPs display good antidepressant effects, and have potential value for clinical application in the prevention and treatment of MDD by regulating the MGB axis. However, in-depth study of the mechanisms by which antidepressant medications affect MGB axis will also require considerable effort in clinical and preclinical research, which is essential for the development of effective antidepressant treatments.
[Display omitted]